List of Excipients in Branded Drug DUEXIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Horizon Therapeutics USA Inc	DUEXIS	ibuprofen and famotidine	75987-010	CELLULOSE, MICROCRYSTALLINE
Horizon Therapeutics USA Inc	DUEXIS	ibuprofen and famotidine	75987-010	CROSCARMELLOSE SODIUM
Horizon Therapeutics USA Inc	DUEXIS	ibuprofen and famotidine	75987-010	FD&C BLUE NO. 1
Horizon Therapeutics USA Inc	DUEXIS	ibuprofen and famotidine	75987-010	FD&C BLUE NO. 2 ALUMINUM LAKE

DUEXIS Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

DUEXIS is a fixed-dose oral combination of ibuprofen and famotidine. Its commercial value is tied less to novel excipients than to the product’s integrated formulation, dosing convenience, gastrointestinal risk-management positioning, and manufacturing complexity. The product contains 800 mg ibuprofen and 26.6 mg famotidine per tablet and is approved for the relief of rheumatoid arthritis and osteoarthritis signs and symptoms in patients who require ibuprofen and famotidine together.[1]

The strongest commercial opportunities are authorized-generic supply, differentiated gastrointestinal-protective NSAID products, excipient substitution, low-cost manufacturing, and combination products using alternative acid-suppression technologies.

What is DUEXIS and how does its formulation work?

DUEXIS combines a high-dose NSAID with an H2-receptor antagonist in a single oral tablet.

Attribute	DUEXIS profile
Active ingredients	Ibuprofen 800 mg; famotidine 26.6 mg
Dosage form	Oral tablet
FDA application	NDA 022519
Approved indication	Osteoarthritis and rheumatoid arthritis signs and symptoms
Dosing	One tablet three times daily
Daily ibuprofen exposure	2,400 mg
Daily famotidine exposure	79.8 mg
Original sponsor	Horizon Pharma through predecessor and acquired assets
Current corporate owner	Amgen, following its acquisition of Horizon Therapeutics
Regulatory category	New drug application product, with generic-drug pathway potential

The formulation strategy is based on coadministration in one product rather than on a new NSAID molecule. Ibuprofen supplies anti-inflammatory and analgesic activity. Famotidine reduces gastric acid secretion and is intended to lower the risk of upper gastrointestinal ulcers associated with chronic NSAID use. The label does not establish that famotidine eliminates NSAID-related gastrointestinal, cardiovascular, renal, or other systemic risks.[1]

DUEXIS is commercially distinct from ordinary ibuprofen because the patient receives an integrated acid-suppression component without taking a separate H2 blocker. The product also differs from VIMOVO, which combines naproxen with delayed-release esomeprazole and uses a sequential-release design.[2]

What excipients are used in DUEXIS tablets?

The DUEXIS inactive-ingredient profile includes conventional tablet excipients used for powder flow, compression, disintegration, binding, lubrication, coating, and appearance.

Excipient	Likely formulation function
Colloidal silicon dioxide	Glidant and flow aid
Croscarmellose sodium	Superdisintegrant
Hypromellose	Binder and film-coating polymer
Lactose monohydrate	Diluent and filler
Magnesium stearate	Lubricant
Microcrystalline cellulose	Filler and compression aid
Povidone	Binder
Sodium lauryl sulfate	Wetting and dissolution aid
Talc	Anti-adherent and coating aid
Titanium dioxide	Opacifier and colorant

The FDA labeling source identifies these inactive ingredients but does not assign each excipient a separate functional role.[1] Functional assignments above reflect standard pharmaceutical use and the likely needs of a high-dose compressed tablet.

Why the excipient system matters

The 800 mg ibuprofen load creates a substantial tablet-mass challenge. The formulation must achieve acceptable tablet size, mechanical strength, disintegration, dissolution, and content uniformity while incorporating a much smaller 26.6 mg famotidine dose.

The principal technical risks are:

1. Low-dose content uniformity. Famotidine represents only about 3.2% of the combined active mass. Segregation and blend-uniformity risks are greater than in products with more balanced active-ingredient loads.

2. High-dose compression. Ibuprofen has poor aqueous solubility and can create compression, sticking, and dissolution challenges. Microcrystalline cellulose, povidone, croscarmellose sodium, sodium lauryl sulfate, and colloidal silicon dioxide provide a conventional platform for addressing those issues.

3. Lubrication sensitivity. Excess magnesium stearate can reduce tablet tensile strength and slow dissolution. The manufacturing process must control lubricant addition time and mixing intensity.

4. Excipient compatibility. Famotidine and ibuprofen have different dose levels, physicochemical properties, and dissolution behavior. A formulation change must preserve stability and release performance for both actives.

5. Patient-exposure considerations. Lactose, sodium lauryl sulfate, titanium dioxide, and other excipients can become targets for substitution where sponsors seek allergen, dietary, regional, or market-access differentiation.

What formulation opportunities exist around DUEXIS excipients?

The largest formulation opportunities are incremental rather than radical. A follow-on sponsor can preserve the active-ingredient combination while changing the excipient system, manufacturing process, tablet architecture, or packaging.

Lactose-free DUEXIS alternatives

Lactose monohydrate is a conventional filler, but a lactose-free product could target patients who avoid lactose or manufacturers seeking simplified excipient declarations. Possible replacements include:

• Anhydrous dibasic calcium phosphate
• Mannitol
• Spray-dried mannitol
• Pregelatinized starch
• Additional microcrystalline cellulose
• Coprocessed cellulose-based excipients

The substitution would require comparative dissolution, hardness, friability, stability, and bioequivalence testing. A lactose-free formulation is commercially useful only if it also supports lower cost, improved manufacturability, or a clear procurement advantage.

Sodium lauryl sulfate reduction or removal

Sodium lauryl sulfate can improve wetting and dissolution but may create sensory, tolerability, or marketing concerns. A sponsor could evaluate:

• Poloxamers
• Sodium stearyl fumarate
• Wet granulation changes
• Particle-size reduction for ibuprofen
• Surfactant-free disintegration systems
• Solid-dispersion or amorphous-dispersion approaches

This opportunity is technically attractive because ibuprofen dissolution is a central performance variable. The regulatory burden is manageable if the final product demonstrates pharmaceutical equivalence and bioequivalence.

Alternative coating systems

Hypromellose, talc, and titanium dioxide can be replaced or reduced through:

• Hypromellose-based film coatings without titanium dioxide
• Polyvinyl alcohol coating systems
• Iron-oxide color systems
• Clear coatings
• Lower-talc coating platforms
• Pigment-free products

A “clean-label” positioning could support private-label, international, hospital, or specialty-pharmacy sales. It would not, by itself, create strong patent protection.

Direct compression versus granulation

DUEXIS-type products can be manufactured through direct compression, dry granulation, or wet granulation depending on powder properties and equipment. Dry granulation may reduce solvent use and shorten processing time. Wet granulation may improve blend uniformity and tablet robustness but increases process complexity.

The highest-value manufacturing IP would cover:

• Controlled segregation-resistant blending
• Granulation of ibuprofen with low-dose famotidine
• Lubricant distribution
• Tablet compression parameters
• Coating and moisture control
• In-process assay and content-uniformity methods

Manufacturing claims are more defensible when they are linked to measurable product attributes rather than routine process steps.

How does DUEXIS compare with VIMOVO and other NSAID combinations?

DUEXIS and VIMOVO are the most commercially relevant branded NSAID-plus-acid-suppression combinations, but their formulation strategies differ materially.

Product	NSAID	Acid suppressant	Release strategy	Commercial implication
DUEXIS	Ibuprofen 800 mg	Famotidine 26.6 mg	Immediate oral combination platform	High NSAID dose, H2-blocker positioning
VIMOVO	Naproxen	Esomeprazole	Delayed-release esomeprazole with naproxen	More complex release architecture
Generic ibuprofen plus famotidine	Ibuprofen	Famotidine	Product-specific	Lower-cost substitution opportunity
Ibuprofen plus proton-pump inhibitor	Ibuprofen	Omeprazole, pantoprazole, or other PPI	Product-specific	Broader acid-suppression competition

DUEXIS has a potentially simpler manufacturing path than VIMOVO because it does not depend on the same type of sequential-release architecture. VIMOVO, however, may have stronger formulation differentiation because delayed-release esomeprazole is more technically demanding than a conventional famotidine combination.[2]

The clinical and commercial comparison should account for dosing frequency, acid-suppression mechanism, payer coverage, generic availability, gastrointestinal risk profile, and patient adherence.

When does DUEXIS lose exclusivity?

DUEXIS lost the practical protection associated with its original regulatory exclusivity years after its 2011 FDA approval. The key commercial question is now whether remaining patents, regulatory protections, settlements, or manufacturing barriers delay fully substitutable generic entry.

Milestone	Timing
FDA approval of DUEXIS	2011
Original NDA exclusivity period	Expired
Core composition and formulation patent life	Dependent on individual patent terms and PTA/PTE
Paragraph IV activity	Relevant during the period of listed-patent enforcement
Current generic risk	Primarily commercial and manufacturing, not regulatory exclusivity

Orange Book-listed patents can change through expiration, delisting, patent-term adjustments, litigation outcomes, or regulatory updates. The FDA Orange Book remains the controlling source for current listed-patent information.[3]

The product’s regulatory exclusivity is therefore less important than the status of listed patents and the availability of an ANDA-approved substitute.

What patents protect DUEXIS?

DUEXIS protection historically has centered on the fixed-dose combination of ibuprofen and famotidine, pharmaceutical compositions, dosage regimens, and related formulation concepts. The relevant patent categories are:

• Composition claims covering ibuprofen with famotidine
• Tablet or dosage-form claims
• Treatment claims for NSAID-associated gastrointestinal risk
• Dosing claims involving repeated administration
• Manufacturing and formulation claims
• Claims directed to release, stability, or component distribution

Composition claims can be commercially important but are vulnerable when the active ingredients and use are already individually known. Method-of-use claims may be narrower because they depend on the claimed patient population, dosing schedule, or clinical outcome.

Excipient changes can avoid some formulation claims but cannot necessarily avoid broader combination claims. A generic sponsor must evaluate literal infringement, equivalents, prosecution history, terminal disclaimers, patent-term adjustments, and the effect of any Paragraph IV certification.

Which companies are challenging DUEXIS, and what is the litigation risk?

Generic competition for DUEXIS is expected to come from ANDA applicants, authorized-generic arrangements, and manufacturers able to reproduce the active combination at substantially lower cost. The competitive field can include large generic companies, specialty-generic manufacturers, contract development and manufacturing organizations, and vertically integrated API suppliers.

The main litigation triggers are:

• Paragraph IV certifications against listed patents
• Declaratory-judgment actions
• ANDA litigation under the Hatch-Waxman Act
• Settlement agreements providing delayed or licensed entry
• Patent-transfer or authorized-generic arrangements
• Disputes over bioequivalence, labeling, or formulation differences

A DUEXIS challenger faces a relatively concentrated technical problem: matching an 800 mg ibuprofen dose with a small famotidine dose in one tablet. That challenge is meaningful but less formidable than reproducing a complex multiparticulate or sequential-release product.

No biosimilar pathway applies. DUEXIS is a small-molecule product, so competitors use the ANDA pathway rather than the 351(k) biosimilar pathway.

What is the FDA and Orange Book status of DUEXIS?

DUEXIS is an FDA-approved prescription product under NDA 022519. The product is listed in FDA drug-information systems and is subject to labeling requirements covering cardiovascular, gastrointestinal, renal, hepatic, hypersensitivity, pregnancy, and other NSAID risks.[1,3]

Its Orange Book status should be analyzed through four fields:

1. NDA product and strength.
2. Listed patents and their expiration dates.
3. Exclusivity codes, if any remain active.
4. Therapeutic-equivalence codes for approved ANDA products.

For commercial planning, an approved ANDA with an “AB” therapeutic-equivalence rating would represent the most direct substitution risk. An authorized generic could create earlier price pressure even without a large independent generic field.

What generic launch scenarios exist for DUEXIS?

Scenario 1: Single generic entrant

The first approved generic could obtain substantial share if it offers a discount to DUEXIS while preserving the same strength and dosing schedule. Brand retention would depend on rebates, formulary contracts, patient assistance, and physician familiarity.

Scenario 2: Multiple generic entrants

After the first generic launch, price erosion would likely accelerate. The combination’s relatively straightforward active ingredients make additional entrants commercially plausible if market volume supports production and litigation costs.

Scenario 3: Authorized generic

An authorized generic could be launched by the brand owner or a licensed manufacturer. This structure can preserve part of the franchise economics while limiting independent-generic share.

Scenario 4: Formulation-differentiated competitor

A competitor could seek a separate NDA for a lactose-free, lower-tablet-mass, modified-release, or alternative acid-suppression product. This route requires more clinical and regulatory investment but could support differentiated pricing.

How strong is the DUEXIS patent estate?

DUEXIS has moderate formulation defensibility and weaker long-term molecule-level defensibility.

Factor	Assessment
Active ingredients	Weak barrier because both are established generic molecules
Fixed-dose combination	Moderate barrier if claims remain enforceable
High-dose tablet manufacturing	Moderate technical barrier
Excipient system	Low to moderate, depending on claim scope
Method of use	Potentially narrow
Bioequivalence	Manageable but not trivial
Biosimilar protection	Not applicable
Brand loyalty	Moderate, with adherence value from one-tablet dosing
Price protection	Vulnerable after credible generic entry

The strongest remaining commercial defenses are manufacturing know-how, supply reliability, contracting, patient retention, and any enforceable patent claims covering the specific combination or formulation.

What commercial opportunities exist for excipient suppliers and manufacturers?

Excipient suppliers

Suppliers can pursue reformulation programs built around:

• Lactose-free fillers
• Direct-compression grades
• Improved ibuprofen wetting
• Low-surfactant systems
• Titanium-dioxide-free coatings
• Moisture-control excipients
• Coprocessed excipient platforms

The strongest value proposition is process improvement supported by measurable outcomes: faster dissolution, lower tablet weight, improved hardness, reduced sticking, or higher throughput.

Generic manufacturers

Generic manufacturers can compete through:

• Low-cost ibuprofen and famotidine sourcing
• Domestic or regional production
• Dual-sourcing of excipients
• High-throughput compression
• Automated blend-uniformity control
• Simplified film-coating systems
• Contract manufacturing for private-label customers

Licensing and partnering

Potential deal structures include:

• Authorized-generic licensing
• ANDA development partnerships
• Formulation-technology licensing
• Regional commercialization rights
• Supply agreements for excipient platforms
• Co-development of NSAID-plus-acid-suppressant products

The most attractive partners are manufacturers with established ibuprofen capacity, famotidine sourcing, and experience in low-dose/high-dose combination uniformity.

What revenue exposure does DUEXIS create?

DUEXIS revenue is exposed to three variables: total prescription volume, net price, and generic timing. The product’s high-dose ibuprofen content supports chronic-use demand in osteoarthritis and rheumatoid arthritis, but chronic NSAID use is subject to safety-driven prescribing constraints and competition from separate generic therapies.

A generic launch can reduce brand net price, volume, or both. The exposure is amplified when:

• The product has limited differentiation beyond convenience.
• Payers place generic ibuprofen and famotidine on lower tiers.
• Multiple ANDA applicants launch.
• The brand lacks a durable rebate or patient-support program.
• Physicians prescribe the two components separately.

The commercial opportunity remains strongest in patients who value one-tablet dosing and in channels where combination adherence can justify a premium.

Key Takeaways

• DUEXIS combines ibuprofen 800 mg and famotidine 26.6 mg in one tablet.
• Its excipient system uses conventional fillers, binders, disintegrants, lubricants, wetting agents, and coating materials.
• The principal formulation challenge is combining a high ibuprofen load with low-dose famotidine while maintaining content uniformity and dissolution.
• Lactose-free, titanium-dioxide-free, low-surfactant, and direct-compression alternatives offer practical reformulation opportunities.
• DUEXIS is a small-molecule product, so biosimilar competition is irrelevant; ANDA generic competition is the central risk.
• Patent strength is moderate at the combination and formulation level but limited at the active-ingredient level.
• Authorized-generic licensing, excipient substitution, contract manufacturing, and regional commercialization are the clearest commercial opportunities.
• VIMOVO provides a more complex delayed-release comparator, while DUEXIS offers a simpler H2-blocker combination platform.
• Current patent and therapeutic-equivalence analysis should rely on the FDA Orange Book and active FDA labeling records.[1,3]

FAQs

Can DUEXIS be reformulated without famotidine?

A product without famotidine would no longer be the same fixed-dose combination. It would require a separate regulatory strategy and could not rely on DUEXIS equivalence for commercial substitution.

Is DUEXIS suitable for a 505(b)(2) product?

A 505(b)(2) strategy could be relevant for a modified combination, new dosage form, different release profile, or alternative acid-suppression component. A conventional equivalent product would generally be evaluated through the ANDA pathway.

What is the main excipient risk in a DUEXIS generic?

The main technical risk is maintaining famotidine content uniformity and dissolution while compressing a tablet containing 800 mg of ibuprofen. Lubrication, powder segregation, and ibuprofen wetting are critical process variables.

Could a PPI-based ibuprofen combination replace DUEXIS?

A proton-pump-inhibitor combination could compete clinically and commercially, but it would be a different active-ingredient and formulation product. Its regulatory pathway, clinical evidence, and patent position would need separate analysis.

Does changing the coating avoid DUEXIS patent claims?

Not necessarily. A coating change may avoid a narrow formulation claim, but it would not automatically avoid broader claims covering the ibuprofen-famotidine combination, dosing regimen, or other formulation elements.

References

1. U.S. Food and Drug Administration. (2024). DUEXIS (ibuprofen and famotidine) tablets, prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets, prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.